Applied Therapeutics

OverviewSuggest Edit

Applied Therapeutics is a clinical-stage biopharmaceutical company developing therapies for diabetic complications. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) that is being developed for the treatment of diabetic cardiomyopathy, or DbCM, fatal fibrosis of the heart. The company is also developing AT-007, a central nervous system penetrant ARI, for the treatment of galactosemia.

TypePublic
Founded2017
HQNew York, NY, US
Websiteappliedtherapeutics.com

Latest Updates

Employees (est.) (Dec 2019)11(+10%)
Share Price (Sept 2021)$15.4(-3%)
Cybersecurity ratingAMore

Key People/Management at Applied Therapeutics

Shoshana Shendelman

Shoshana Shendelman

CEO & Founder
Riccardo Perfetti

Riccardo Perfetti

Chief Medical Officer
Charles Silberstein

Charles Silberstein

Chief Financial Officer
Adam Hansard

Adam Hansard

Chief Commercial Officer
Show more

Applied Therapeutics Office Locations

Applied Therapeutics has an office in New York
New York, NY, US (HQ)
545 5th Ave #1400
Show all (1)

Applied Therapeutics Financials and Metrics

Applied Therapeutics Revenue

USD

Net income (Q1, 2021)

(24.2m)

EBIT (Q1, 2021)

(24.2m)

Market capitalization (7-Sept-2021)

401.7m

Closing stock price (7-Sept-2021)

15.4

Cash (31-Mar-2021)

84.1m

EV

319.2m
Applied Therapeutics's current market capitalization is $401.7 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

582.0k2.0m13.2m32.7m

R&D expense

3.7m11.5m32.4m61.8m

Operating expense total

4.3m13.5m45.6m94.5m

EBIT

(4.3m)(13.5m)(45.6m)(94.5m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

General and administrative expense

1.9m4.2m3.3m5.2m7.5m9.8m

R&D expense

6.9m4.3m7.5m7.3m20.8m14.4m

Operating expense total

8.7m8.4m10.7m12.5m28.3m24.2m

EBIT

(8.7m)(8.4m)(10.7m)(12.5m)(28.3m)(24.2m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

3.3m18.7m18.9m57.5m

Prepaid Expenses

9.0k1.5m7.3m5.8m

Current Assets

3.3m20.2m46.2m102.6m

Total Assets

3.3m20.2m48.4m104.5m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

14.7m41.1m13.1m92.5m100.9m84.1m

Prepaid Expenses

2.2m5.7m4.1m9.4m10.0m6.3m

Current Assets

16.9m46.8m37.0m163.7m148.5m154.4m

Total Assets

16.9m46.8m37.3m165.9m150.6m156.2m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(4.3m)(16.5m)(45.5m)(94.0m)

Accounts Payable

5.8m(8.0m)

Cash From Operating Activities

(3.2m)(11.2m)(36.3m)(78.2m)

Cash From Investing Activities

(20.0m)(19.5m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(8.7m)(17.2m)(27.9m)(12.4m)(40.4m)(24.2m)

Accounts Payable

(366.0k)462.0k(1.3m)(7.2m)(3.1m)2.8m

Cash From Operating Activities

(7.0m)(16.1m)(23.9m)(18.9m)(34.8m)(22.2m)

Cash From Investing Activities

(19.9m)(41.7m)(17.7m)(24.7m)
USDFY, 2017

Financial Leverage

1.4 x
Show all financial metrics

Applied Therapeutics Operating Metrics

Q1, 2019

Phase II Patients Enrolled

120
Show all operating metrics

Applied Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Applied Therapeutics Online and Social Media Presence

Embed Graph

Applied Therapeutics News and Updates

Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association

NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a Product Theater presenta…

Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Dru…

Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at th…

Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference

NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the…

Applied Therapeutics Reports First Quarter 2021 Financial Results

Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency

Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster presentation at …
Show more

Applied Therapeutics Blogs

Applied Therapeutics Reports Second Quarter 2021 Financial Results

Applied Therapeutics Reports Second Quarter 2021 Financial Results Content Import Thu, 08/12/2021 - 07:00 Applied Therapeutics Reports Second Quarter 2021 Financial Results Aug 12, 2021 This release is a backfill from a News Wire General …

Applied Therapeutics Added to Russell Microcap® Index

Applied Therapeutics Added to Russell Microcap® Index Content Import Mon, 06/28/2021 - 07:00 Applied Therapeutics Added to Russell Microcap® Index Jun 28, 2021 This release is a backfill from a News Wire General NEW YORK, June 28, 2…

Applied Therapeutics to be Added to NASDAQ Biotechnology Index

Applied Therapeutics to be Added to NASDAQ Biotechnology Index Content Import Tue, 12/15/2020 - 08:00 Applied Therapeutics to be Added to NASDAQ Biotechnology Index Dec 15, 2020 This release is a backfill from a News Wire General NEW…

Applied Therapeutics Reports Third Quarter 2020 Financial Results

Applied Therapeutics Reports Third Quarter 2020 Financial Results Content Import Thu, 11/12/2020 - 07:01 Applied Therapeutics Reports Third Quarter 2020 Financial Results November 12, 2020 at 7:00 AM EST This release is a backfill from a News Wire …

Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2020

Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2020 Content Import Mon, 11/09/2020 - 07:03 Applied Therapeutics Announces Presentation of Pre-Clinical Data o…

Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2020 Annual Meeting

NEW YORK , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present two
Show more

Applied Therapeutics Frequently Asked Questions

  • When was Applied Therapeutics founded?

    Applied Therapeutics was founded in 2017.

  • Who are Applied Therapeutics key executives?

    Applied Therapeutics's key executives are Shoshana Shendelman, Riccardo Perfetti and Charles Silberstein.

  • How many employees does Applied Therapeutics have?

    Applied Therapeutics has 11 employees.

  • Who are Applied Therapeutics competitors?

    Competitors of Applied Therapeutics include Auxulin Pharmaceuticals, Abarceo Pharma and glyscend.

  • Where is Applied Therapeutics headquarters?

    Applied Therapeutics headquarters is located at 545 5th Ave #1400, New York.

  • Where are Applied Therapeutics offices?

    Applied Therapeutics has an office in New York.

  • How many offices does Applied Therapeutics have?

    Applied Therapeutics has 1 office.